Kamada Ltd is a biopharmaceutical company that specializes in the development and commercialization of innovative therapeutics for rare and serious diseases. The company focuses on producing protein-based drugs, particularly in the fields of immunology and respiratory medicine, utilizing its proprietary technology platforms. By developing therapies that address unmet medical needs, Kamada aims to improve the quality of life for patients while advancing healthcare solutions in specialized treatment areas. The company actively engages in partnerships and collaborations to enhance its research and development efforts, striving to bring new and effective treatments to market. Read More
Kamada Ltd (KMDA) reported mixed Q2 2025 earnings, with revenue slightly below estimates but EPS beating forecasts. Stock rose pre-market as profitability outlook improved.
DETROIT, MICHIGAN - June 11, 2025 ( NEWMEDIAWIRE ) - Kamada Ltd. ( NASDAQ: KMDA) recently reported earnings for the first quarter of 2025, which saw revenue up 17% and Adjusted EBITDA up 54% year-over-year. The results help position Kamada to drive growth organically, as well as through acquisitions and/or in-licensing deals.
DETROIT, MICHIGAN - June 6, 2025 ( NEWMEDIAWIRE ) - Cytomegalovirus (CMV) is a common virus that most adults are exposed to at some point in their lives, and over half of American adults have been infected by age 40 . A healthy immune system can keep the virus at bay, and it’s usually harmless. But for organ transplant recipients, contracting CMV disease can be dangerous and even deadly in some cases. About 20% to 60% of people who have a solid organ transplant develop a symptomatic CMV infection. It's one of the most common complications for solid organ transplant recipients. While effective strategies that often use antiviral medicines to prevent or treat CMV exist, none offer a completely foolproof solution, nor is there any vaccine available to prevent it in advance.
DETROIT, MICHIGAN - April 16, 2025 ( NEWMEDIAWIRE ) - Amir London, CEO of Kamada Pharmaceuticals (NASDAQ: KMDA), was recently a guest on Benzinga’s All-Access.
NEW YORK CITY, NY / ACCESS Newswire / March 18, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 19-20, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
